James Raftery: Ever higher cancer drug prices—driven by US policies and genetic sequencing

The high prices charged by companies for cancer drugs has led to lots of speculation, but very little explanation. The most interesting attempt to explain these high prices has been made by a US oncologist Scott Ramsey. As the article is paywalled, I summarise it below (with thanks to the author for a copy). His […]

Read More…